Clinical Trials Logo

Graft Versus Host Disease clinical trials

View clinical trials related to Graft Versus Host Disease.

Filter by:

NCT ID: NCT03419078 Completed - Clinical trials for Graft Versus Host Disease

Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)

Start date: December 2015
Phase:
Study type: Observational

Retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.

NCT ID: NCT03414645 Completed - Dry Eye Clinical Trials

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

Start date: May 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye drops in patients with Dry Eye Disease (DED) secondary to Graft vs. Host Disease (GvHD).

NCT ID: NCT03339297 Completed - Clinical trials for Graft-versus-host Disease

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Start date: February 21, 2018
Phase: Phase 2
Study type: Interventional

This is a study comparing the defibrotide prophylaxis arm vs standard of care arm for the prevention of aGvHD.

NCT ID: NCT03207958 Completed - Clinical trials for Graft Vs Host Disease

Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

Start date: May 16, 2018
Phase: Phase 1
Study type: Interventional

Given the role of B cells in the pathophysiology of chronic graft versus host disease (GvHD), the association between elevated BAFF levels post-transplant in abnormal B-cell homeostasis and chronic GvHD, and the efficacy of belimumab in the inhibition of soluble human B lymphocyte stimulator protein (BAFF) signaling, these proof-of-principle findings support the rational for use of belimumab as prophylaxis of chronic GvHD. The investigators propose a pilot and feasibility study to assess the safety and tolerability, as well as preliminary efficacy, of belimumab as prophylaxis of chronic GvHD following allogeneic hematopoietic cell transplantation (alloHCT). The investigators' central hypothesis is that belimumab will be well tolerated and have a favorable effect on incidence and severity of chronic GvHD.

NCT ID: NCT03204721 Completed - Clinical trials for Graft-Versus-Host Disease

Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis

GVHD
Start date: June 21, 2017
Phase: N/A
Study type: Interventional

The main aim is to test the preventive use of extracorporeal photophoresis (ECP) against development of graft-versus-host disease (GVHD) in patients undergoing allogeneic stem cell transplantation for hematological malignancy.

NCT ID: NCT03128359 Completed - Clinical trials for Myelodysplastic Syndrome

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Start date: May 30, 2017
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well high dose cyclophosphamide, tacrolimus, and mycophenolate mofetil work in preventing graft versus host disease in patients with hematological malignancies undergoing myeloablative or reduced intensity donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft versus host disease). Giving high dose cyclophosphamide, tacrolimus, and mycophenolate mofetil after the transplant may stop this from happening.

NCT ID: NCT03124056 Completed - Clinical trials for Graft-versus-host Disease

Clinical and Biomarker Study of the Efficacy of Extracorporeal Photopheresis in Graft-versus-host Disease

BIOECP_GVHD
Start date: January 10, 2013
Phase: N/A
Study type: Observational [Patient Registry]

The aims of the study: 1. To evaluate the clinical efficacy of the use of extracorporeal photopheresis in the treatment of Graft-versus-host disease under standard clinical indications as pre-defined by the participants Centers (members of the Spanish Group for Hematopoietic Transplantation). 2. To explore and identify biomarkers of clinical response to extracorporeal photopheresis treatment of acute or chronic Graft-versus-host disease after Allogeneic hematopoietic stem cell transplantation

NCT ID: NCT02942173 Completed - Lymphoma Clinical Trials

CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT

Start date: October 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this prospective randomized study is to determine whether infusions of T-memory cells prevent infections in children with leukemia after allogeneic alpha, beta T-cell receptor (TcRab)/CD19-depleted hematopoietic stem cell transplantation (HSCT).

NCT ID: NCT02891395 Completed - Clinical trials for Graft Versus Host Disease

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

DoubleITK
Start date: December 24, 2012
Phase: Phase 2
Study type: Interventional

Open label non-randomized multicenter phase 2 trial with direct individual benefice

NCT ID: NCT02867800 Completed - Sickle Cell Disease Clinical Trials

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Start date: July 2016
Phase: Phase 1
Study type: Interventional

To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving early alemtuzumab followed by fludarabine, thiotepa, melphalan, and alemtuzumab for conditioning.